Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer

NCT02216487 is registered in ClinicalTrials.gov with Western General Hospital, Australia as lead sponsor.

NCT NCT02216487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02216487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer
Lead sponsor
Western General Hospital, Australia
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2014
Completion date
November 30, 2016
Enrollment
45 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer